SCHEMBL19343270

SCHEMBL19343270

COC(=O)/C(=C/c1ccc(OC)cc1Cl)N=[N+]=[N-]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCD O00767 1/20 0.38
▸ MAPT P10636 3/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ TYK2 P29597 1/20 0.36
▸ TRIM24 O15164 1/20 0.35
▸ TYR P14679 1/20 0.35
▸ TRIM33 Q9UPN9 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.34
▸ FLT1 P17948 1/20 0.34
▸ FLT4 P35916 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ LY96 Q9Y6Y9 1/20 0.34
▸ ABCG2 Q9UNQ0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19330982 0.89 TRIM24 (0.36) MAPTTRIM24TYRTRIM33ALDH1A1
SCHEMBL19330978 0.89 TRIM24 (0.36) MAPTTRIM24TYRTRIM33ALDH1A1
SCHEMBL20536245 0.87 SMN1; SMN2 (0.37) ALDH1A1LMNAHPGD
SCHEMBL20536246 0.87 SMN1; SMN2 (0.37) ALDH1A1LMNAHPGD
SCHEMBL29015479 0.87 SMN1; SMN2 (0.37) ALDH1A1LMNAHPGD
SCHEMBL27891901 0.86 MAPT (0.48) MAPTALDH1A1KMT2AMEN1HPGD
SCHEMBL26372679 0.86 GABRA1 (0.42) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL22166661 0.85 CYP1A1 (0.41) SCDMAPTTRIM24TYRTRIM33
SCHEMBL29443039 0.85 CYP1A1 (0.41) SCDMAPTTRIM24TYRTRIM33
SCHEMBL24113139 0.85 CA1 (0.39) MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-10-05 — — US disclosed
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-10-05 — — US disclosed
US-11634412-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2023-04-25 — — US disclosed
US-11634412-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2023-04-25 — — US disclosed
US-20230009122-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-01-12 — — US disclosed
US-20230009122-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-01-12 — — US disclosed
WO-2017156165-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-09-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11634412-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD SCD 442/4885MAPT 2286/4885JAK2 4131/4885
US-20230009122-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD SCD 442/4885MAPT 2286/4885JAK2 4131/4885
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD SCD 442/4885MAPT 2286/4885JAK2 4131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback